Clinical and molecular characteristics of MTAP loss versus MTAP unaltered pancreatic cancer patients from the Niguarda Cancer Center cohort
| MTAP loss cohort | MTAP intact cohort | P value | |
| No of patients | 12 | 24 | |
| Median age at diagnosis (IQR) | 63 (51–72) | 65 (57–71) | 0.750 |
| Gender (%) | |||
| Male | 5 (41.7) | 14 (58.3) | 0.483 |
| Female | 7 (58.3) | 10 (41.7) | |
| Stage at diagnosis (%) | 0.725 | ||
| Non metastatic | 5 (41.7) | 13 (54.2) | |
| Metastatic | 7 (58.3) | 11 (45.8) | |
| Tumour mutational burden (IQR) | 1.26 (0.00–4.10) | 2.52 (1.58–4.73) | 0.210 |
| Microsatellite instability (%) | 0.0 | 0.0 | NA |
| CDKN2A/B loss (%) | 12 (100.0) | 1 (4.2) | <0.001 |
| RAS mutant (%) | 23 (95.8) | 12 (100.0) | 1.000 |
MTAP, methylthioadenosine phosphorylase; NA, not available.